OBJECTIVES: To characterize the clonality of TMPRSS2-ERG fusion in multifocal prostate cancer. METHODS: From 80 consecutive radical prostatectomy specimens, we identified 32 cases with multiple spatially separate tumors. In each case, we assessed two to three tumor foci for TMPRSS2-ERG fusion using an ERG break-apart interphase fluorescence in situ hybridization assay. RESULTS: Individual tumor foci showed homogeneity for fusion status (intrafocal clonal homogeneity). In 19 (59%) of the 32 cases, all foci within a case had the same fusion status (interfocal homogeneity). In 15 (80%) of the 19 cases, no foci had fusion, and in 4 (20%), all foci had fusion. Of the 32 cases, 13 (41%) demonstrated heterogeneity for fusion status within a case (interfocal clonal heterogeneity). CONCLUSIONS: In this study, we have demonstrated interfocal heterogeneity and intrafocal homogeneity for TMPRSS2-ERG fusion in prostate cancer with multiple tumors. These findings support the multiclonal nature of prostate cancer with clinical implications for needle biopsy strategies and the development of urine-based screening tests.
OBJECTIVES: To characterize the clonality of TMPRSS2-ERG fusion in multifocal prostate cancer. METHODS: From 80 consecutive radical prostatectomy specimens, we identified 32 cases with multiple spatially separate tumors. In each case, we assessed two to three tumor foci for TMPRSS2-ERG fusion using an ERG break-apart interphase fluorescence in situ hybridization assay. RESULTS: Individual tumor foci showed homogeneity for fusion status (intrafocal clonal homogeneity). In 19 (59%) of the 32 cases, all foci within a case had the same fusion status (interfocal homogeneity). In 15 (80%) of the 19 cases, no foci had fusion, and in 4 (20%), all foci had fusion. Of the 32 cases, 13 (41%) demonstrated heterogeneity for fusion status within a case (interfocal clonal heterogeneity). CONCLUSIONS: In this study, we have demonstrated interfocal heterogeneity and intrafocal homogeneity for TMPRSS2-ERG fusion in prostate cancer with multiple tumors. These findings support the multiclonal nature of prostate cancer with clinical implications for needle biopsy strategies and the development of urine-based screening tests.
Authors: Scott A Tomlins; Daniel R Rhodes; Sven Perner; Saravana M Dhanasekaran; Rohit Mehra; Xiao-Wei Sun; Sooryanarayana Varambally; Xuhong Cao; Joelle Tchinda; Rainer Kuefer; Charles Lee; James E Montie; Rajal B Shah; Kenneth J Pienta; Mark A Rubin; Arul M Chinnaiyan Journal: Science Date: 2005-10-28 Impact factor: 47.728
Authors: L Cheng; S Y Song; T G Pretlow; F W Abdul-Karim; H J Kung; D V Dawson; W S Park; Y W Moon; M L Tsai; W M Linehan; M R Emmert-Buck; L A Liotta; Z Zhuang Journal: J Natl Cancer Inst Date: 1998-02-04 Impact factor: 13.506
Authors: Bharathi Laxman; Scott A Tomlins; Rohit Mehra; David S Morris; Lei Wang; Beth E Helgeson; Rajal B Shah; Mark A Rubin; John T Wei; Arul M Chinnaiyan Journal: Neoplasia Date: 2006-10 Impact factor: 5.715
Authors: Sven Perner; Francesca Demichelis; Rameen Beroukhim; Folke H Schmidt; Juan-Miguel Mosquera; Sunita Setlur; Joelle Tchinda; Scott A Tomlins; Matthias D Hofer; Kenneth G Pienta; Rainer Kuefer; Robert Vessella; Xiao-Wei Sun; Matthew Meyerson; Charles Lee; William R Sellers; Arul M Chinnaiyan; Mark A Rubin Journal: Cancer Res Date: 2006-09-01 Impact factor: 12.701
Authors: Andrea Sboner; Francesca Demichelis; Stefano Calza; Yudi Pawitan; Sunita R Setlur; Yujin Hoshida; Sven Perner; Hans-Olov Adami; Katja Fall; Lorelei A Mucci; Philip W Kantoff; Meir Stampfer; Swen-Olof Andersson; Eberhard Varenhorst; Jan-Erik Johansson; Mark B Gerstein; Todd R Golub; Mark A Rubin; Ove Andrén Journal: BMC Med Genomics Date: 2010-03-16 Impact factor: 3.063
Authors: Cindy Ke Zhou; Denise Young; Edward D Yeboah; Sally B Coburn; Yao Tettey; Richard B Biritwum; Andrew A Adjei; Evelyn Tay; Shelley Niwa; Ann Truelove; Judith Welsh; James E Mensah; Robert N Hoover; Isabell A Sesterhenn; Ann W Hsing; Shiv Srivastava; Michael B Cook Journal: Am J Epidemiol Date: 2017-12-15 Impact factor: 4.897
Authors: Sean R Williamson; Shaobo Zhang; Jorge L Yao; Jiaoti Huang; Antonio Lopez-Beltran; Steven Shen; Adeboye O Osunkoya; Gregory T MacLennan; Rodolfo Montironi; Liang Cheng Journal: Mod Pathol Date: 2011-04-15 Impact factor: 7.842
Authors: Juan-Miguel Mosquera; Sven Perner; Elizabeth M Genega; Martin Sanda; Matthias D Hofer; Kirsten D Mertz; Pamela L Paris; Jeff Simko; Tarek A Bismar; Gustavo Ayala; Rajal B Shah; Massimo Loda; Mark A Rubin Journal: Clin Cancer Res Date: 2008-06-01 Impact factor: 12.531
Authors: Sven Perner; Maria A Svensson; Ruhella R Hossain; John R Day; Jack Groskopf; Ryan C Slaughter; Analee R Jarleborn; Matthias D Hofer; Rainer Kuefer; Francesca Demichelis; David S Rickman; Mark A Rubin Journal: Urology Date: 2010-04 Impact factor: 2.649
Authors: Scott A Tomlins; Nallasivam Palanisamy; Javed Siddiqui; Arul M Chinnaiyan; Lakshmi P Kunju Journal: Arch Pathol Lab Med Date: 2012-08 Impact factor: 5.534
Authors: Raquel Esgueva; Sven Perner; Christopher J LaFargue; Veit Scheble; Carsten Stephan; Michael Lein; Florian R Fritzsche; Manfred Dietel; Glen Kristiansen; Mark A Rubin Journal: Mod Pathol Date: 2010-01-29 Impact factor: 7.842